

e) automatically determining one or more neurite features selected from the group consisting of:

- i) Total neurite length from all cells;
- ii) Total number of neurite branches from all cells;
- iii) Number of neurites per cell;
- iv) Number of neurites per positive neuron;
- v) Neurite length from each cell;
- vi) Neurite length per positive neuron;
- vii) Neurite length per neurite;
- viii) Number of cells that are positive for neurite outgrowth;
- ix) Percentage of cells positive for neurite outgrowth;
- x) Number of branches per neuron; and
- xi) Number of branches per neurite.

> to determine neurite outgrowth.

22. [20] (AMENDED) The method of claim 21 [19], wherein identifying cell bodies comprises the steps of:

- A) generating a kernel image from the nuclear image;
- B) performing conditional dilations of the kernel image to identify the cell body.

23. [21] (AMENDED) The method of claim 22 [20], wherein identifying neurites extending from cell bodies comprises the steps of:

- I) generating a reservoir image from the neurite image; and
- II) identifying positive pixels in the reservoir image that are not present in the cell bodies, wherein such positive pixels belong to neurites extending from cell bodies.

24. [22] (AMENDED) The method of claim 23 [21], further comprising

- (a) performing one conditional dilation of the kernel image to acquire a dilation image;
- (b) determining a set of nodes from the dilation image;
- (c) linking together connected nodes; and
- (d) repeating steps (a)-(c) until an entire neurite length has been traced.

25. [23] (AMENDED) The method of claim 24 [22], wherein steps (a) through (d) are carried out at multiple time points.

- 10
Civil
26. [24] (AMENDED) The method of claim 21 [19] further comprising contacting the neurons with a test compound, and determining an effect of the test compound on neurite outgrowth from the cell bodies.
 27. [25] (AMENDED) The method of claim 26 [24], further comprising contacting the neurons with a neurotoxin either before, after, or simultaneously with the test compound.
 28. [26] (AMENDED) The method of claim 26 [24], further comprising contacting the cells with a control compound known to stimulate neurite outgrowth, and determining whether the test compound inhibits the control compound from inducing neurite outgrowth from the cell bodies.
 29. [27] (AMENDED) The method of claim 21 [19], wherein steps b) through e) are carried out at multiple time points.
 30. [28] (AMENDED) The method of claim 21 [19] wherein the first luminescently labeled reporter molecule comprises a DNA binding compound.
 31. [29] (AMENDED) The method of claim 21 [19] wherein the second luminescently labeled reporter molecule is neuron-specific.
 32. [30] (AMENDED) The method of claim 31 [29] wherein the neuron-specific luminescent reporter molecule comprises a molecule selected from the group consisting of neurofilament proteins, β III-tubulin, ciliary neurotrophic factor, and antibodies specific for neurofilament proteins.

Based on all of the above, the Applicants believe the claims are now allowable. If there are any questions or comments regarding this response, the Examiner is encouraged to contact the undersigned agent as indicated below.

Respectfully submitted,

Date: 7/3/03



David S. Harper

Registration No. 42,636

McDonnell Boehnen
Hulbert & Berghoff, Ltd.
300 South Wacker Drive
Chicago, IL 60606

Telephone: 312-913-0001
Facsimile: 312-913-0002